The treatment of human African trypanosomiasis.
Pépin
J
J
Service des Maladies Infectieuses, Centre Hospitalier Universitaire, Sherbrooke, Québec, Canada.
Milord
F
F
D000818:Animals; D004133:Diminazene / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D000518:Eflornithine / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D008549:Melarsoprol / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D009547:Nifurtimox / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D010419:Pentamidine / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D013498:Suramin / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D014344:Trypanocidal Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D014347:Trypanosoma brucei gambiense; D016833:Trypanosoma brucei rhodesiense; D014353:Trypanosomiasis, African / Q000188:drug therapy*
D014344:Trypanocidal Agents; D013498:Suramin; D010419:Pentamidine; D009547:Nifurtimox; D004133:Diminazene; D008549:Melarsoprol; D000518:Eflornithine